(NASDAQ: XENE) Xenon Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.32%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.27%.
Xenon Pharmaceuticals's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast XENE's revenue for 2024 to be $1,885,812,050, with the lowest XENE revenue forecast at $1,885,812,050, and the highest XENE revenue forecast at $1,885,812,050. On average, 1 Wall Street analysts forecast XENE's revenue for 2025 to be $5,657,436,150, with the lowest XENE revenue forecast at $5,657,436,150, and the highest XENE revenue forecast at $5,657,436,150.
In 2026, XENE is forecast to generate $5,498,273,613 in revenue, with the lowest revenue forecast at $2,813,631,579 and the highest revenue forecast at $7,872,888,146.